Oncology Biosimilars Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026

The report on the global oncology biosimilars market provides qualitative and quantitative analysis for the period from 2018 to 2026. The report predicts the global oncology biosimilars market to grow with a CAGR of 30.25m% over the forecast period from 2020-2026. The study on oncology biosimilars market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026.

The report on oncology biosimilars market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global oncology biosimilars market over the period of 2018 to 2026. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global oncology biosimilars market over the period of 2018 to 2026. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• The global rise in the number of geriatric patient’s population and increasing incidences of cancer
• Increasing investment in the biosimilars or biological drugs by the major key players

2) Restraints

• Regulatory requirements, patent issues, and varying physician and patient preferences may restrain the growth

3) Opportunities

• Increasing focus on new drug development and expiration of patented biologics

Research Methodology

A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global oncology biosimilars market is segmented on the basis of application, and end-user.

The Global Oncology Biosimilars Market by Application

• Cancer Treatment Drugs
• Supportive Care Drugs

The Global Oncology Biosimilars Market by End-user

• Hospitals
• Retail Pharmacies

Company Profiles
The companies covered in the report include

• Biocon Limited
• Amgen Inc.
• Sandoz International GmbH
• Biogen
• Roche Holding AG
• Biocad Biopharmaceutical Co
• Dr. Reddy's Laboratories Limited
• Pfizer Inc.
• Momenta Pharmaceuticals Inc.
• Mylan Pharmaceuticals Inc.

What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the oncology biosimilars market.
2. Complete coverage of all the segments in the oncology biosimilars market to analyze the trends, developments in the global market and forecast of market size up to 2026.
3. Comprehensive analysis of the companies operating in the global oncology biosimilars market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.